A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)
Latest Information Update: 21 Mar 2023
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Acronyms NOZOMI
- Sponsors AstraZeneca
Most Recent Events
- 01 Mar 2023 Results assessing the long-term safety of tezepelumab in Japanese patients with severe uncontrolled asthma published in the Journal of Asthma
- 27 Sep 2022 According to an AstraZeneca media release, results from the trial were published in The Journal of Asthma in June 2022.
- 17 Jun 2021 Status changed from active, no longer recruiting to completed.